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Abstract 
The acute and chronic effects of repeated intravitreal anti-vascular endothelial growth factor (VEGF) 
injections on intraocular pressure (IOP) have not been fully characterized and the development of 
sustained ocular hypertension could adversely affect patients who are at risk of glaucomatous optic 
neuropathy. As expected, volume-driven, acute ocular hypertension immediately follows intravitreal 
injection, but this pressure elevation is generally transient and well-tolerated.  Several medications have 
been investigated to limit acute ocular hypertension following anti-VEGF therapy, but the benefits of 
pretreatment are not conclusive. Chronic, sustained ocular hypertension, distinct from the short-term 
acute ocular hypertension following each injection, has also been associated with repeated intravitreal 
anti-VEGF injections.  Risk factors for chronic ocular hypertension include the total number of injections, 
a greater frequency of injection, and pre-existing glaucoma.  Proposed mechanisms for chronic ocular 
hypertension include microparticle obstruction, toxic or inflammatory effects on trabecular meshwork, 
as well as alterations in outflow facility by anti-VEGF agents. Although limiting anti-VEGF therapy could 
minimize the risk of both acute and chronic ocular hypertension, foregoing anti-VEGF therapy risks 
progression of various macular diseases with resulting permanent central vision loss. While definitive 
evidence of damage to the retinal nerve fiber layer is lacking, patients receiving repeated injections 
should be monitored for ocular hypertension and those who subsequently develop sustained ocular 
hypertension should be periodically monitored for glaucomatous changes with an optic nerve optical 
coherence tomography (OCT) and static visual fields.  
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I. Introduction 
Anti-vascular endothelial growth factor (anti-VEGF) therapy has proliferated over the past 
decade.   In 2004, intravitreal pegaptanib (Macugen®) was the first anti-VEGF agent approved for any 
ophthalmic indication after administration every 6 weeks was shown to decrease vision loss by half 
compared to sham in the treatment of neovascular AMD (nAMD).41  Subsequently, in Genentech’s 
MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of 
nAMD) and ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal 
Neovascularization in Age-Related Macular Degeneration Study) trials investigating monthly intravitreal 
ranibizumab (Lucentis®) in nAMD, subjects experienced a mean improvement in  visual acuity of 7.2 and 
11.3 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, respectively, at 1 year, compared to 
a  mean loss of 10.4 and 9.5 ETDRS letters in the sham and verteforpin control groups, respectively.16, 96 
Ranibizumab 0.5 mg was approved for the treatment of nAMD in 2006, a major milestone because, for 
the first time, a treatment improved vision in nAMD, as opposed to simply ameliorating decline. Several 
years later, Regeneron’s VIEW (Vascular Endothelial Growth Factor VEGF Trap-Eye: Investigation of 
Efficacy and Safety in Wet Age-Related Macular Degeneration) randomized control trials (RCTs) of 
intravitreal aflibercept (Eylea®) demonstrated monthly and bimonthly regimens of aflibercept were non-
inferior to monthly ranibizumab over a 1-year time period,44 and led to the approval of aflibercept 2 mg 
for the treatment of nAMD in 2011.  Simultaneously, off-label intravitreal bevacizumab 1.25 mg 
(Avastin®) was found to be noninferior to ranibizumab in the Comparison of AMD Treatments Trials 
(CATT), a National Institutes of Health sponsored RCT.77  
Anti-VEGF therapy for the treatment of diabetic macular edema (DME) and macular edema due 
to retinal vein occlusions was subsequently adopted, after several studies demonstrated a significant 
benefit for these indications.15, 18, 27  Because of the remarkable benefit of anti-VEGF therapies in these 
disorders, their use has exploded from essentially 0 in 2004 to over 16 million intravitreal anti-VEGF 
injections performed in 2016, comprising a global market of over $8 billion annually (www.market-
scope.com).  Coinciding with this burst in anti-VEGF therapy, reports of associated sustained ocular 
hypertension surfaced. Confounding this issue, however, is an aging population at risk of both 
developing glaucoma and acquiring pathologies necessitating anti-VEGF therapy.  In addition, both vein 
occlusion and diabetes are known risk factors for glaucoma.  Consequently, the acute and chronic ocular 
hypertensive effects of repeated anti-VEGF therapy has not been effectively characterized.55, 56, 63 We 
review the short- and long-term effects of intravitreal anti-VEGF injections on IOP and the optic nerve, 
as well as the prophylactic measures that have been investigated to reduce immediate post-injection 
IOP spikes. In addition, this review presents the theoretical mechanisms for anti-VEGF-related chronic 
ocular hypertension.   
 
II. Short-term ocular hypertensive effects of intravitreal anti-VEGF injections 
Anti-VEGF regimens typically involve long-term monthly or periodic intravitreal injections (IVI) of 
50 µl of therapy via a small gauge needle, most often without paracentesis.  As expected, ocular 
hypertension immediately follows from a volume effect, but this is generally transient and well-
tolerated in the vast majority of patients.   
 
A. Intraocular pressure trend following anti-VEGF injection 
A significant, transient rise in IOP occurs following anti-VEGF injection of 50 µl into an 
average vitreous volume of 4.5 -5.0 ml. Figure 1 demonstrates the IOP trend immediately 
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following injection and it is a weighted average of 14 studies that are summarized in 
Supplemental Material Table 1.25, 30, 31, 33, 38, 51, 62, 66, 71, 73, 82, 85, 101, 113  IOP rises to an average of 46 
mmHg and then quickly decreases to pre-injection measurements within 1 hour in eyes without 
significant abnormalities in trabecular meshwork outflow facility. 
 
B.        Risk factors for acute ocular hypertension following injection 
Numerous risk factors for the severity of acute ocular hypertension following IVI have 
been investigated, including the absence of post-injection subconjunctival reflux, smaller 
needles, tunneled injection techniques, and a prior diagnosis of glaucoma.  
The greatest risk factor for acute ocular hypertension is the absence of subconjunctival 
reflux. Table 1 presents four studies that investigated the effect of subconjunctival reflux on 
immediate post-injection IOP and reveals that the IOP immediately following IVI averages 20 
mmHg lower in patients with reflux.69, 72, 88, 101  The occurrence of reflux is often overlooked by 
busy clinicians and is difficult to quantitate, but represents a potentially important risk factor for 
ocular hypertension following IVI. Reflux depends on the injection technique and size of the 
needle. Larger bore needles create a wider needle track through the sclera, resulting in a greater 
chance of reflux. Several studies have demonstrated that smaller bore needles have less post-
injection reflux and a higher IOP.50, 69, 87, 88  Similarly, tunneled injection techniques allow the 
needle track to be pinched off by the edge of the sclera, reducing the amount of reflux and 
increasing post-injection IOP.69, 87  
A second important risk factor for severe, acute ocular hypertension and delayed 
recovery is a prior history of glaucoma.10, 66 Bakri et al. found that 10 minutes after IVI of 
bevacizumab, triamcinolone, or pegaptanib, only 75% of glaucomatous patients recovered to an 
IOP of less than 35 mmHg in contrast with 95.5% of patients without glaucoma.10 This 
observation supports the notion that glaucomatous eyes suffer from pathologically 
compromised aqueous humor outflow; however, studies demonstrating a correlation between 
the diagnosis of glaucoma and the severity of ocular hypertension following IVI are primarily 
limited by small sample sizes.  Further investigations are necessary to confirm and quantify this 
observation. 
Another suspected risk factor for acute ocular hypertension is a smaller vitreous volume 
manifested by a short axial length. The literature supporting this hypothesis is mixed.17, 38, 39, 47, 71, 
87 Surprisingly, the volume of injected drug has not been confirmed to be a risk factor. Bakri et 
al. assessed three different volumes (triamcinolone 0.1 mL, pegaptanib 0.09 mL and 
bevacizumab 0.05 mL) and found no difference in the post-injection IOP change;10 however, this 
observation is likely confounded by the variety of needle gauges used for the different 
medications. Triamcinolone is generally injected with a 27-gauge needle, resulting in a greater 
incidence of reflux and counteracting the hypertensive effects of the greater volume injected.  It 
seems intuitive that larger volumes would likely result in greater IOP change when controlling 
for confounding variables.  
 
C.        Studies supporting medical prophylaxis for acute ocular hypertension following IVI 
Several medications have been investigated to limit acute ocular hypertension following 
anti-VEGF therapy, and five studies, discussed in detail below, have found topical agents to be 
mildly effective at prophylactically decreasing IOP (Figure 3).26, 65, 86, 91, 107  A major limitation of 
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these studies is the lack of recording and control for subconjunctival reflux. Additionally, each 
study uses different IOP cutoffs and observation times following injection, making comparison 
between studies difficult.  Finally, the clinical benefit of a mild decrease in a short-duration IOP 
spike remains unclear. 
 
1.  Apraclonidine 
Apraclonidine decreases aqueous production and increases both trabecular and 
uveoscleral outflow.108 These pressure-dependent and pressure-independent 
mechanisms are effective at reducing the IOP spike following anterior segment laser 
procedures, cataract surgery and vitrectomy, making apraclonodine a promising 
investigational agent to limit acute ocular hypertension following IVI.95 El Chehab et al. 
prospectively assessed the effect of 1 drop of 1% apraclonidine administered 
prophylactically 2 hours prior to injection. The study included 250 patients who were 
randomized to five study arms, receiving either prophylactic apraclonidine, oral 
acetazolamide, brimonidine-timolol, dorzolamide-timolol, or no prophylaxis (control). 
Immediately following injection, the average IOP measured 37.3 mmHg in the 
apraclonidine group in comparison to 46.4 mmHg in the control group. The proportion 
of patients with an IOP of >45 mmHg was 65.5% in the control group and 7.7% in the 
apraclonidine group. At 15 minutes, the proportion of patients with an IOP of >25 
mmHg was 0.0% in the apraclonidine group and 36.6% in the control group.26 
Consequently, apraclonidine appeared more effective than oral acetazolamide at 
decreasing acute ocular hypertension following IVI, and appeared similarly effective to 
the brimonidine-timolol and dorzolamide-timolol topical formulations.  
  
2.  Timolol 
Timolol decreases aqueous production and is well tolerated by patients.14 Pece 
et al. prospectively randomized 150 patients to receive either no prophylactic 
medication, timolol 0.1% gel the evening before injection, or timolol 0.1% gel 2 hours 
prior to injection.  Five minutes following injection, the use of timolol gel 2 hours prior to 
injection resulted in an average pressure of 25.5 mmHg in comparison to 29.3 mmHg in 
the control group. The proportion of patients with an IOP spike of > 40 mmHg was 
reduced from 18% to 2% with the use of timolol 2 hours prior to injection. The use of 
timolol 0.1% gel the evening before injection had no effect on IOP control.91 While direct 
comparison with other protocols is challenging, these results are suggestive that timolol 
gel is slightly less effective than the apraclonidine, dorzolamide-timolol and 
brimonidine-timolol formulations evaluated by Chehab et al.26  
 
3.  Dorzolamide-Timolol 
Timolol decreases aqueous production through sympathetic blockade of the 
nerve endings in the ciliary epithelium 14 and dorzolamide reduces aqueous production 
by blocking carbonic anhydrase.75 Three studies have assessed the prophylactic effect of 
the dorzolamide-timolol combination prior to IVI. A summary of the studies and their 
IOP-lowering effects are displayed in table 2.26, 65, 86 All three studies demonstrated a 
mild decline in IOP immediately following injection. Kim et al. observed that the 
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dorzolamide-timolol group had a modest decrease in IOP in comparison to the control 
group at 5 minutes (14.1 mmHg versus 28.2 mmHg) and at 1 hour (10.7 mmHg versus 
18.7 mmHg), but dorzolamide-timolol was not more effective than the brinzolamide-
timolol combination.65 These studies suggest that dorzolamide-timolol has similar 
efficacy to apraclonidine and brimonidine-timolol at mildly lowering the severity of post-
injection acute ocular hypertension. 
 
4.  Brimonidine-timolol 
Brimonidine suppresses aqueous production, increases uveoscleral outflow and 
has possible neuroprotective properties.42, 97 Two studies have investigated the 
prophylactic effect of brimonidine-timolol drops.  
Theoulakis et al. prospectively investigated the prophylactic effect of 1 drop of 
brimonidine-timolol given twice a day, the day prior to and the day of injection.  Eighty-
eight patients were randomized to equally sized groups, one receiving brimonidine-
timolol and the other receiving no drops. At 5 minutes the treated group had an average 
IOP of 28.4 mmHg compared to an average pressure of 34.1 mmHg in the control group. 
At 15 minutes, none of the patients in the treatment group had a pressure of >20 
mmHg, as compared to 34% in the control group.107 
El Chehab et al., as previously discussed, assessed the effect of 1 drop of 
brimonidine-timolol given 2 hours prior to injection. Fifty patients were randomized to 
receive either brimonidine-timolol or four other investigational arms (control, 
apraclonidine, oral acetazolamide, dorzolamide-timolol). Immediately following 
injection, the IOP was 38 mmHg in the brimonidine-timolol group and 46.4 mmHg in the 
control group. At 15 minutes, the percentage of patients with an IOP of >25mmHg was 
0% in the brimonidine-timolol group and 36.6% in the control group.26 Brimonidine-
timolol showed a greater prophylactic effect than control, and was similarly effective to 
apraclonidine and dorzolamide-timolol topical formulations.  
 
5.  Brinzolamide-timolol 
Brinzolamide-timolol combines the aqueous suppression from carbonic 
anhydrase inhibition with the aqueous suppression from ciliary epithelial sympathetic 
pathway blockage.14, 46 Kim et al. prospectively investigated the effects of 1 drop of 
brinzolamide-timolol given 1 hour prior to injection. Patients were divided into three 
groups: 84 in the brinzolamide-timolol arm, 53 in the dorzolamide-timolol arm and 29 in 
the control arm. After 5 minutes, the IOP in the brinzolamide-timolol group averaged 
14.87 mmHg as compared to 28.21 mmHg in the control arm. After 1 hour, the average 
IOP in the brinzolamide-timolol group was 13.61 mmHg, in comparison to 18.72 mmHg 
in the control arm. Topical brinzolamide-timolol showed similar effectiveness to 
dorzolamide-timolol. 
 
D. Studies not supporting medical prophylaxis for acute ocular hypertension following IVI  
Oral acetazolamide is a potent carbonic anhydrase inhibitor 98, and its 
effectiveness in angle-closure glaucoma makes it a promising agent in the prophylaxis 
against acute ocular hypertension following IVI. Surprisingly, two studies have assessed 
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oral acetazolamide prior to injection and noted no IOP lowering effect, although it is 
possible that the dosing and timing were not optimized for this indication. 
Murray et al. compared 12 patients receiving 500 mg PO acetazolamide 60-90 
minutes prior to injection with 12 control patients. There was no statistically significant 
difference in pressures immediately after, 5 minutes after or 10 minutes after the 
injection. At 30 minutes, the average IOP in the treatment arm was 15.7 mmHg and in 
the control arm was 20.6 mmHg, which was statistically significant.83  
El Chehab et al. compared 50 patients receiving 250 mg of oral acetazolamide 
given 2 hours prior to injections with three other treatment arms (apraclonidine, 
dorzolamide-timolol, brominidine-timolol) and 50 patients in a control arm. No 
difference in IOP was found between the control arm and the oral acetazolamide arm.26  
 
E.   Other prophylactic measures for acute ocular hypertension following IVI 
1.  Anterior chamber paracentesis 
More effective than topical and oral treatments, anterior chamber (AC) 
paracentesis effectively prevents a post-injection IOP spike, but introduces additional 
risks of infection and iatrogenic injury. Knip et al. demonstrated the effectiveness of an 
AC paracentesis, showing that the average immediate post-injection IOP was 15.3 
mmHg in the paracentesis group as compared to 47.1 mmHg in the control group. At 2 
minutes and at 30 minutes there was no statistically significant difference between 
groups.70  
Despite the effectiveness, there are risks of performing an AC paracentesis. A 
study assessing 560 paracenteses showed 4 complications (0.7%).109 Two patients 
experienced inadvertent injection of sterile air into the anterior chamber which 
spontaneously resolved without adverse consequences. One patient experienced a 
small anterior lens capsule laceration that was self-sealing, but left a localized opacity 
and another patient experienced an allergic reaction to povidone iodine.109  Other case 
studies have demonstrated complications such as endophthalmitis and infectious 
keratitis.5, 45, 57   
Although AC paracentesis involves some minimal risk, in patients at risk of 
glaucomatous progression who are known to experience transient vision loss related to 
severe acute ocular hypertension following IVI, an anterior chamber paracentesis could 
be appropriate.  In these patients, the transient vision loss is likely from severely 
elevated pressures that result in hypoperfusion to the retina.  
 
2.  Ocular decompression 
One study assessed the effect of ocular decompression by cotton swabs on 
post-injection acute ocular hypertension. Forty-eight patients were divided into two 
groups. One group was anesthetized with a cotton swab soaked in 4% lidocaine and 
received ocular decompression, and a control group received 3.5% lidocaine gel 
anesthetic without ocular decompression. The immediate post-injection IOP was 25.7 
mmHg in the decompression group and 30.9 mmHg in the control group.  The 
proportion of patients with IOP of >50 mmHg was 10% in the decompression group and 
35% in the control group.43 These findings support the beneficial effect of moderate 
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ocular pressure prior to injection. A similar principle has been applied using the Honan 
Intraocular Pressure Reducer, which applies gentle pressure to an eye before a 
procedure. One study supported the prophylactic anti-hypertensive effect of this device, 
while another study showed no benefit.52, 67   
 
F. Summary of studies investigating prophylaxis against acute ocular hypertension following 
intravitreal injection 
Numerous medications have been investigated to prophylactically reduce acute ocular 
hypertension following anti-VEGF IVIs, and most topical drops have a similar mild 
effectiveness at decreasing IOP. Surprisingly, oral acetazolamide has little effect at 
lowering IOP based on material currently published. Overall, the benefits of 
pretreatment with ocular anti-hypertensive agents prior to IVI is not conclusive, mainly 
because of the questionable clinical benefit in slightly decreasing IOP over the short 
duration before IOP normalizes. However, it can be argued that patients with advanced 
glaucomatous optic neuropathy may benefit from a slight reduction in pressure and 
prophylactic treatment can be considered, particularly because these patients are more 
susceptible to further damage from increased pressures and may be at increased risk of 
higher IOP spikes over a greater duration of time due to underlying outflow pathology. 
An AC paracentesis is a more effective, albeit riskier, method at preventing acute ocular 
hypertension in at-risk patients. 
 
III. Long-term effects of intravitreal anti-VEGF injections 
A.          Studies associating sustained ocular hypertension with chronic anti-VEGF injections 
 Repeated intravitreal anti-VEGF injections have been associated with chronic ocular 
hypertension, distinct from the short-term acute ocular hypertension following each injection, in 
a subset of patients.  Numerous case reports and case series have suggested this phenomenon 
and those with incidence rates are summarized in Table 3.2-4, 6, 19, 34, 59, 76, 79, 80, 93, 99, 110 In some cases, 
the ocular hypertension was severe enough to warrant surgical filtration.23, 104  
Post hoc analyses of major anti-VEGF trials have provided the best evidence in support 
of this phenomenon. While numerous retrospective case series have similarly supported this 
finding, as demonstrated in Table 3, their nonrandomized nature and typically smaller cohort 
provide inferior quality of evidence.  On analysis of the MARINA and ANCHOR studies, Bakri et 
al. noted the proportion of patients who had at least one visit with an increase in pre-injection 
IOP of 6 mmHg or more from baseline with a concurrent IOP ≥21 mmHg was 26.1% in the 0.5 
mg ranibizumab group, 23.6% in the 0.3 mg Ranibizumab group and 13.6% in the sham/PDT 
groups.9 The proportion of patients with at least one IOP measurement of 21 mmHg or more 
was 39.9% in the 0.5 mg ranibizumab group, 37.0% in the 0.3 mg ranibizumab group and 29.1% 
in the sham/PDT groups.9 These findings are suggestive that a subgroup of patients develop 
sustained ocular hypertension due to chronic anti-VEGF therapy and are also suggestive of a 
possible dose-related response. A post-hoc analysis of DRCR data found that 9.5% of patients in 
the ranibizumab plus prompt or deferred focal/grid laser group experienced sustained IOP 
elevation versus 3.5% of patients in the sham injection plus focal/grid laser treatment group.13 
The difference in the percentage of affected patients between the DRCR and MARINA/ANCHOR 
trials is due to different definitions of sustained ocular hypertension. Similar findings were 
presented in a post-hoc analysis of the IVAN study.32 Additionally, a recent population-based, 
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nested, case-control study in Canada found that patients receiving 7 or more annual injections 
had a greater odds ratio of undergoing glaucoma drainage surgery than controls.23 The major 
limitations of these and other studies listed in Table 3 are their retrospective nature and their 
uncontrolled methods of IOP measurement, as IOPs were variably measured with the use of a 
tonopen or Goldmann applanation tonometer. Glaucoma trials typically utilize standardized 
protocol-driven IOP measuring regimens, such as requiring two masked individuals to measure 
IOP with only Goldmann applanation tonometry, to minimize the risk of bias or error.   
Risk factors for chronic ocular hypertension in these studies are intuitive. The total 
number of injections was demonstrated to be a risk factor,11, 40, 48, 49, 93, 99 as was a greater 
frequency of injections79 and a pre-existing diagnosis of glaucoma prior to initiation of IVIs.22, 40 
Fruend et al. observed that ranibizumab, as compared to aflibercept, had higher rates of ocular 
hypertension, with 8.4% of patients on monthly ranibizumab having an IOP of greater than 
21mmHg on two consecutive visits compared to 3.2% and 2.7% of patients who received 2 mg 
and 0.5 mg of aflibercept every month, respectively.34 While the Freund et al. analysis has been 
the only study to directly compare aflibercept with ranibizumab, ranibizumab was not 
associated with greater rates of sustained OHTN in comparison to bevacizumab in other 
studies.2, 3, 40, 48, 68 In fact, Good et al. observed that patients receiving ranibizumab had lower 
rates of sustained OHTN compared to bevacizumab (3.1% versus 9.9%).40 It remains to be seen if 
one medication is consistently associated with higher rates of sustained OHTN.  A history of 
cataract extraction or a posterior capsulotomy, with a theoretical increased rate of diffusion of 
medication to the anterior chamber, were not observed to be risk factors. 
Recently, Wen et al. investigated the conventional outflow facility of patients receiving 
chronic anti-VEGF therapy, utilizing electronic Schiøtz tonography. They found a small but 
statistically significant decrease in outflow facility in patients with a greater number of IVIs 
(≥20). Additionally, they found eyes with contralateral ocular hypertension had a two-fold 
reduction in outflow facility following anti-VEGF therapy as compared to the contralateral 
eye.112 This functional study supports the observation that the total number of injections is a risk 
factor for sustained ocular hypertension. It also supports the notion that chronic anti-VEGF 
therapy can reduce outflow capacity. Finally, it is suggestive of a two-hit hypothesis, where 
patients with underlying ocular hypertension and pathological outflow capacity, are at increased 
risk of further outflow reduction due to chronic anti-VEGF therapy. A two-hit hypothesis may 
also explain why only a fraction of patients developed sustained ocular hypertension.   
A multitude of theoretical mechanisms have been described in an effort to explain the 
reduced outflow capacity and the sustained rise in IOP observed in a subset of patients receiving 
recurrent intravitreal anti-VEGF injections. One of the proposed mechanisms involves 
microparticle obstruction of the trabecular meshwork.20 Some studies have demonstrated that 
silicone microdroplets from syringes and protein aggregates from medication packaging or 
delivery equipment can obstruct aqueous outflow.7, 60, 74 This is of particular relevance with the 
advent of prefilled ranibizumab syringes, and patients receiving this therapy should be observed 
for the development of sustained ocular hypertension due to possible microparticle obstruction 
from materials that become dissolved in the anti-VEGF solution. Kahook et al. reported 
variations in the concentration of high-molecular-weight protein aggregates in different samples 
of compounded and repackaged bevacizumab.60 In addition, Good et al. reported a sustained 
IOP elevation in 9.9% of patients receiving bevacizumab compared with 3.1% in patients 
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receiving ranibizumab. Given that bevacizumab (149 kDa) is approximately 3 times larger than 
ranibizumab (48 kDa), it is thought that the high-molecular-weight proteins may accumulate in 
the trabecular meshwork and obstruct aqueous outflow.2, 8, 40 
Another proposed mechanism involves the direct effects on trabecular meshwork cells 
by intravitreal anti-VEGF agents. In vitro studies by Kahook et al. demonstrated that 4 mg/mL of 
bevacizumab slows the metabolism and replication of trabecular meshwork cells.58 This was not 
demonstrated with lower concentrations of bevacizumab (2 mg/mL) or with ranibizumab;58 
However, Kernt et al. reported no toxic effects to the trabecular meshwork with bevacizumab at 
the 1.25 mg/0.05 mL concentration used in intravitreal injections.61 Others have proposed that 
monomer antibodies, aggregated proteins, or other high molecular weight molecules may incite 
an underlying inflammatory reaction leading to trabeculitis with impaired aqueous humor 
outflow.37, 81, 105 
In addition to the mechanical obstruction and the potential toxic and inflammatory 
effects on the trabecular meshwork, some have proposed alterations in outflow facility by anti-
VEGF agents.  VEGF receptors have been found to be expressed on the trabecular meshwork 
and Schlemm’s canal endothelial cells. Schlemm’s canal cells express vascular endothelial (VE) 
cadherin, an endothelial cell adhesion molecule.92  VEGF stimulation promotes the 
endocytosis of VE cadherin, and VEGF blockade can disrupt this barrier function and reduce 
endothelial cell permeability.36 Other in vitro models have similarly demonstrated that VEGF 
induces endothelial fenestrations.29 In addition, nitric oxide has been shown to increase anterior 
chamber aqueous outflow through a reduction in trabeculocyte size and smooth muscle 
contractility with Schlemm’s canal vasodilation. Anti-VEGF therapy disrupts the 
normal nitric oxide signaling pathway by inhibition of nitric oxide synthase.94 Animal studies 
have demonstrated that VEGF increases aqueous humor outflow facility and that blockage of 
VEGF receptors leads to ocular hypertension.35 Anti-VEGF inhibition of the disassembly of the 
endothelial intercellular junctions, decrease in the endothelial fenestrations, and inhibition of 
nitric oxide production are a few of the biochemical mechanisms that may explain the impaired 
outflow and sustained rise in IOP.   
Although there is no clear consensus on which of these proposed mechanisms 
contributes most to the rise in IOP, various studies support that anti-VEGF injections may have 
an effect on the trabecular meshwork pressure-dependent outflow system. 
 
B.   Studies not associating sustained ocular hypertension with chronic anti-VEGF 
injections 
The main limitation of post-hoc analyses supporting the ocular hypertensive effects of 
anti-VEGF IVIs is that IOP was not the primary outcome measured. Consequently, IOP 
measurement was not standardized and  both applanation and tonopen methods were used to 
varying degrees.54 Publication bias may also limit the submission and acceptance of studies 
observing no increase in rates of sustained ocular hypertension. Another source of bias is the 
inclusion of the cases that initiated a study, which may artificially elevate observed incidence 
rates of ocular hypertension. Finally, other studies have demonstrated conflicting results. Wehrli 
et al. did not observe an increased risk of sustained ocular hypertension in patients receiving 
frequent intraocular injections as compared to fellow untreated eyes, and similar results were 
demonstrated in other studies summarized in Table 4.12, 64, 68, 84, 111, 114 The strengths of the 
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Wehrli et al. and Kim et al. studies are their fellow-eye control and large patient number.68, 111 
Interestingly, Kim et al. found higher rates of sustained ocular hypertension in patients with 
underlying glaucoma and a history of retinal vein occlusion.68 Even though not correspondingly 
observed by Wehrli et al., these findings may support the notion that patients with underlying 
outflow pathology are susceptible to the effects of repeated anti-VEGF therapy. While the 
studies by Kim et al. and Wehrli et al. are well-constructed retrospective analyses, the evidence 
provided by the retrospective analysis of the MARINA, ANCHOR and DRCR studies, all of which 
support the hypothesis of a subset of patients developing sustained OHTN, provide better 
quality evidence due to their larger size and lower likelihood for selection bias.  
 
C.  Effect of repeated injections on the retinal nerve fiber layer 
Average retinal nerve fiber layer (aRNFL) thinning on optic nerve OCT is expected if anti-
VEGF agents and associated ocular hypertension are harmful to ganglion cells and their axons. 
Most studies have found no correlation between repeated injections and aRNFL thickness.21, 24, 
28, 53, 100, 102, 106 One study, in contrast, found an aRNFL thinning of -5.5 μm following a mean of 4.8 
injections.78 Two studies found an aRNFL thinning in injected eyes but found a similar thinning in 
the control eyes.90, 103  Overall, these studies suggest a minimal average effect of repeated anti-
VEGF injections on aRNFL thickness in patients receiving multiple injections. However, there are 
major limitations in the interpretation of these results. All of the studies mentioned above 
excluded patients with a history of glaucoma and therefore cannot allow for any conclusions 
about repeat injections on aRNFL thickness in patients with glaucoma – though the disease 
process itself would be expected to show progressive aRNFL thinning. In addition, 6 of 8 studies 
that investigated the effect of injection frequency had fewer than 7 mean injections, and 5 of 8 
studies that investigated duration of follow-up observed patients for less than 15 months. These 
studies may be missing patients who develop aRNFL thinning after a greater number of 
injections given over a longer period of time. Additionally, as observed by the post hoc analysis 
of the MARINA, ANCHOR and DRCR studies, only a subset of patients develop sustained ocular 
hypertension, and analysis of patients as a whole who receive anti-VEGF IVIs may miss the 
proportion of affected patients.  
One study has evaluated the effect of an underlying diagnosis of glaucoma on the aRNFL 
thinning. Park et al. found that a greater number of injections was associated with aRNFL 
thinning in glaucomatous patients compared to those without glaucoma.89 These results are 
consistent with studies finding a greater IOP rise in patients with an underlying diagnosis of 
glaucoma and repeated injections;22, 40 however, an obvious limitation of the Park study is the 
lack of control for natural glaucoma progression, as these patients may have had RNFL thinning 
regardless of IVI. Overall, glaucomatous patients may be more susceptible to RNFL thinning with 
repeated anti-VEGF injections given the underlying damage to the ganglion cells, their axons, 
the trabecular meshwork and downstream outflow pathways; however, available evidence does 
not definitively support this hypothesis. 
 
IV. Macular disease and the risks of forgoing anti-VEGF therapy 
Foregoing anti-VEGF therapy risks progression of various macular diseases. The MARINA study 
demonstrated a dramatic improvement in mean visual acuity of 7.2 ETDRS letters after one year of 
ranibizumab therapy compared to a loss of 10.4 ETDRS letters without treatment (for a net 17.6 ETDRS 
letter benefit); at one year, monthly treatment decreased the risk of losing 15 ETDRS letters from 37.8% 
to 5.5%.96 Unfortunately, a decreased intensity of anti-VEGF treatment in an as-needed regimen may 
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yield an inferior result, as the CATT study demonstrated a mean difference of 2.4 ETDRS letters in favor 
of the monthly versus the as-needed regimen after two years.77  
The benefit of anti-VEGF therapy has been similarly demonstrated in macular edema in diabetic 
retinopathy and retinal vein occlusions.15, 18, 27  For example, in the DRCR protocol I study of diabetic 
macular edema (DME), subjects in the ranibizumab/deferred laser group experienced a mean gain of 9 
ETDRS letters after 2 years, in contrast to those in the prompt laser group who experience a mean 
improvement of only 3 ETDRS letters.27  
In the BRAVO study of macular edema due to branch retinal vein occlusion, subjects in the 
ranibizumab group experienced a mean gain of 18.3 ETDRS letters at 6 months in contrast to those in 
the sham group who experienced a mean improvement of only 7.3 ETDRS letters at 6 months.18 In the 
CRUISE study of macular edema associated with central retinal venous occlusions, subjects in the 
ranibizumab group experienced a mean gain of 14.9 ETDRS letters at 6 months in contrast to those in 
the sham group who experienced a mean improvement of only 0.8 ETDRS letters.15  
For macular edema with diabetic retinopathy or branch vein occlusion, an alternative to anti-
VEGF medications could be macular laser photocoagulation, which generally reduces vision loss by 50%.1 
Unfortunately, for exudative AMD, no effective alternative therapy exists and forgoing anti-VEGF 
therapy places patients at a significantly increased risk of vision loss. 
 
 
V. Conclusion 
Although anti-VEGF therapy is well tolerated in the vast majority of patients, acute and chronic 
ocular hypertension following treatment merits consideration.  We have discussed the degree and 
timing of ocular hypertension immediately following anti-VEGF IVIs. IOP typically rises acutely following 
IVI with normalization within 30-60 minutes.  In glaucomatous patients, this ocular hypertension is more 
dramatic and of longer duration. Numerous medications have been investigated to reduce 
prophylactically acute ocular hypertension, and all topical drops have a similar mild effect in decreasing 
IOP following IVI. Surprisingly, oral acetazolamide has little effect on lowering IOP following IVI based on 
material currently published. Overall, the benefits of pretreatment with ocular anti-hypertensive agents 
prior to IVI is not conclusive, mainly because of the questionable clinical benefit in slightly decreasing 
IOP over the short duration before IOP normalizes; however, it can be argued that patients with 
advanced glaucomatous optic neuropathy may benefit from a slight reduction in pressure, and 
prophylactic treatment can be considered  because these patients are more susceptible to further 
damage from increased pressures and may be at increased risk of higher IOP spikes over a greater 
duration of time. An AC paracentesis is a more effective, albeit riskier, intervention to prevent acute 
ocular hypertension in at-risk patients.  
Chronically, a subset of patients likely develop persistent ocular hypertension.  Several studies 
did not find a correlation between chronic anti-VEGF therapy and sustained OHTN. However, post hoc 
analyses of the MARINA, ANCHOR and DRCR studies provides the best quality evidence that a subset of 
patients develop a clinically significant elevation in intraocular pressure following chronic anti-VEGF 
intravitreal therapy.  Evaluation of these studies are suggestive that patients who have underlying 
outflow pathology, as manifested by an underlying diagnosis of glaucoma, ocular hypertension or a 
history of retinal vein occlusion, are at particular risk of developing sustained ocular hypertension and 
these patients should be closely monitored for the development of sustained pressure elevation. A 
history of cataract extraction or posterior capsulotomy were not consistently identified as risk factors, 
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and the particular anti-VEGF utilized was not conclusively observed as a risk factor. Further studies are 
necessary to clarify which particular anti-VEGF therapy, if any, has increased rates of sustained ocular 
hypertension. Although definitive evidence of damage to the retinal nerve fiber layer is lacking, patients 
receiving repeated injections should be monitored for the development of ocular hypertension and 
those who develop sustained ocular hypertension should be periodically monitored for glaucomatous 
changes with an optic nerve OCT and static visual field. Referrals to a glaucoma specialist should be 
considered in patients with concerning features.  
This review allows for a better risk-benefit analysis for clinicians providing frequent intravitreal 
anti-VEGF injections. Future studies, potentially assessing subconjunctival reflux, are needed to further 
clarify the role of prophylactic medications prior to IVI for acute ocular hypertension. In addition, longer-
duration prospective studies or larger, population-based retrospective studies focusing on progression 
of glaucomatous optic neuropathy following IVI could help clarify the long-term risk of anti-VEGF 
therapy and aid in identifying which subset of patients are at risk of developing sustained ocular 
hypertension. 
 
Literature Search 
Prospective randomized trials, prospective cohort studies, and retrospective studies that 
reported on IOP following intravitreal injections of anti-VEGF agents were searched using Medline 
through November, 2017. Key words included in the search included intraocular pressure, IOP, optical 
coherence tomography, OCT, intravitreal, intraocular, anti-VEGF, VEGF, vascular endothelial growth 
factor, Lucentis, ranibizumab, Avastin, bevacizumab, Eylea, aflibercept, Macugen, pegaptanib, injection, 
and injections. Inclusion criteria included prospective randomized trials, retrospective case series, 
retrospective case reports and injection of anti-VEGF medications. Exclusion criteria included literature 
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Table 1.  
Effect of subconjunctival reflux on ocular hypertension immediately following intravitreal anti-VEGF 
injections. This table demonstrates the effect of subconjunctival reflux on ocular hypertension 
immediately following IVI. A 19.9 mmHg difference exists between eyes that experience reflux with 
those that do not.  
Study 
Medications 
and Volume 
Needle 
gauge 
Number of patients 
IOP increase from baseline 
immediately following IVI (mmHg) 
With 
reflux 
Without 
reflux With reflux Without reflux 
Sharei 
2010 
Ranibizumab 
0.05 mL 
30 20 23 17.4 33 
Pang 
2015 
Ranibizumab 
0.05 mL, 
aflibercept 
0.05 mL 
30 and 
32 
22 43 8.3 29.6 
Lemos 
2014 
Bevacizumab 
0.05 mL 
30 62 229 7.7 28.6 
Knecht 
2009 
Ranibizumab 
0.05 mL, 
bevacizumab 
0.05 mL 
30 20 10 5.2 22.5 
Weighted Average IOP (mmHg) 9.0 28.9 
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Table 2.  
The 
effec
t of 
dorz
olam
ide-
timo
lol at 
redu
cing 
acut
e 
post-
IVI 
ocul
ar 
hype
rtens
ion.  
Study 
IVI drug and 
volumes 
Dorzolamide-
timolol 
regimen 
Number of 
patients Key findings 
El 
Chehab 
2013 
Ranibizumab 
0.05 mL 
1 drop of 
dorzolamide-
timolol given 2 
hours before 
injection 
- 50 patients in 
dorzolamide-
timolol arm, - 50 
patients in each 
of 4 other arms: 
   - Control 
   - Apraclonidine 
   - Oral 
acetazolamide 
   - Brimonidine-
timolol 
Immediately following 
injection, the IOP was 36.9 
mmHg in the dorzolamide-
timolol arm and 46.4 mmHg 
in the control arm; an IOP 
spike of >45 mmHg occurred 
in 20.0% of the dorzolamide-
timolol arm and 65.5% in 
control arm. Dorzolamide-
timolol was not more 
effective than apraclonidine 
or brimonidine-timolol. 
Kim 2013 Ranibizumab 
0.05 mL or 
Bevacizumab 
0.05 mL 
1 drop of 
dorzolamide-
timolol given 1 
hour before 
injection 
- 53 patients in 
the dorzolamide-
timolol arm - 84 
in the 
brinzolamide-
timolol arm 
- 29 in the 
control arm  
At 5 minutes, the 
dorzolamide-timolol group 
had an IOP of 14.1 mmHg 
compared to control group 
of 28.2 mmHg. At 1 hour, the 
average IOP was 10.7 mmHg 
in the dorzolamide-timolol 
group and 18.7 mmHg in the 
control group. Dorzolamide-
timolol was not more 
effective than brinzolamide-
timolol. 
Ozcaliskin 
2015 
Bevacizumab 
0.05 mL 
1 drop of 
dorzolamide-
timolol given 2 
hours before 
injection 
- 75 patients in 
treatment arm 
- 76 patients in 
control arm 
At 1 minute, average IOP of 
was 29.8 mmHg in the 
treated arm and 34.4 mmHg 
in the control arm. At 30 
minutes, the average 
pressure equalized.  
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Table 3. Studies findings a subgroup of patients experiencing sustained ocular hypertension following repeated intravitreal injections.  
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Study Cohort Med # of IVI 
before 
OHTN 
Follow-
up 
Key IOP inclusion 
criteria 
Key findings 
Adelman 
2010 
116 patients with AMD B, R 13.3 -- IOP >21 mmHg on 2 
separate 
measurements 
-       3.4 % of patients developed OHTN 
-       Average IOP prior to injections: 13 mm Hg 
-       Average IOP when OHTN developed: 31.75 mmHg 
- YAG capsulotomy a possible risk factor 
Baek 
2010 
152 patients with AMD 
and DME 
B -- 18.7 
months 
IOP increase of 5mmHg 
above baseline IOP on 
2 consecutive visits 
- 5.9% of patients developed sustained OHTN  
- Number of injections was a risk factor 
Choi 
2011 
155 eyes with AMD R, B, 
P 
9.6 13.9 
months 
IOP >25 mmHg on at 
least two separate visit 
- 5.5% of eyes developed sustained OHTN 
- Number of injections, medication used and injection frequency were not 
risk factors 
- One eye required trabeculectomy 
- Anti-VEGF agent used was not a risk factor 
Good 
2011 
215 eyes with AMD B, R 5 -- IOP ≥ 22 mmHg lasting 
≥ 30 days on at least 
two separate visits and 
a change from baseline 
of >6 mmHg 
- 6% of patients developed sustained OHTN 
- 33% of patients with pre-existing glaucoma developed sustained OHTN  
- 9.9% of patients receiving bevacizumab developed sustained OHTN, in 
comparison to 3.1% of patients receiving ranibizumab 
Hoang 
2012 
207 consecutive patients 
with AMD 
B, R 24.4 37.2 
months 
Multiple Percentage of patients with >5mmHg increase on ≥2 consecutive visits 
- Treated: 11.6%  
- Control: 5.3% 
Percentage of patients with >10 mmHg increase on ≥2 consecutive visits 
- Treated: 4.8%  
- Control: 0.5% 
The total number of injections was a risk factor for IOP elevation 
Mathalo
ne 2012 
201 eyes with AMD B 5 15.7 
months 
IOP ≥22 mmHg and a 
change from baseline 
of ≥6 mmHg at two 
consecutive visits at 
least >30 days apart 
- Sustained IOP was found in 11% of patients 
- Risk factors included male gender and interval between injections of less 
than 8 weeks 
- Pre-existing glaucoma and YAG capsulotomy were not risk factors 
Menke 
2013 
320 eyes with AMD R 13.0 22.7 
months 
-- - Mean increase in IOP was 0.8 mmHg 
- Seven eyes showed a final IOP between 22 and 25 mmHg 
- Duration of treatment was associated with greater increase in pressure 
Agard 
2014 
217 eyes with AMD B, R 6.1 -- IOP >25 mmHg on 2 
consecutive visits 
- 4.6 % of patients developed sustained OHTN 
- 1.4% of patients had sustained IOP > 30 mmHg 
- Average IOP for sustained OHTN group: 29 mmHg 
- OAG at presentation was associated with an increased risk of sustained 
IOP > 25 mmHg (12.9% versus 3.2%, p < 0.001) 
- YAG capsulotomy was not a risk factor 
Bakri 
2014 
1125 patients with AMD, 
from MARINA and 
R -- 
 
24 
months 
Multiple cutoff criteria IOP of 21 mmHg or more with a concurrent IOP increase of 6 mmHg or more 
from baseline (p <0.0001 for all comparisons): 
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Table key: 
IVI: Intravitreal injection, IOP: Intraocular pressure, AMD: Age-related macular degeneration, R: Ranibizumab, B: Bevacizumab, A: Aflibercept, A0.5: Aflibercept 
0.5 mg/0.05 mL, OHTN: Ocular hypertension, DME: Diabetic macular edema, Rq4: Ranibizumab every 4 weeks, A2q4: Aflibercept 2 mg every 4 weeks, A2q8: 
Aflibercept 2mg every 8 weeks, A0.5q4: Aflibercept 0.5 mg every 4 weeks 
 
ANCHOR studies,  
excluding patients that 
were crossed over to the 
treatment arm 
 - Ranibizumab 0.5 mg: 26.1 % 
- Ranibizumab 0.3 mg: 23.6 % 
- Sham:  13.6 % 
IOP of 25 mmHg or more with a concurrent IOP increase of 6 mmHg or more 
from baseline (p <0.003 for all comparisons): 
- Ranibizumab 0.5 mg: 9.6% 
- Ranibizumab 0.3 mg: 9.4% 
- Sham: 3.7% 
Control in this study was the fellow eye, which did not show a similar pattern 
of sustained OHTN 
Al-
Abdullah 
2015 
760 eyes with diabetic 
macular edema 
B, R 5.45 17.9 
months 
IOP increase of 
>6mmHg from baseline 
OR IOP of >24 on 2 or 
more consecutive visits 
- 1.7 % of patients developed sustained OHTN 
- Total number of injections was a risk factor for sustained OHTN 
- YAG capsulotomy or pseudophakia was not a risk factor 
Bressler 
2015 
582 eyes, 322 of which 
received ranibizumab 
plus prompt or deferred 
laser. Retrospective 
analysis of DRCR study  
R -- 36 
months 
IOP of 22 mmHg or 
more with a 
concomitant increase 
in IOP of 6 mmHg or 
more from baseline at 
2 consecutive visits 
 
Percentage of patients with sustained OHTN at 1 year 
- Ranibizumab: 5.7% 
- Sham 2.0% 
Percentage of patients with sustained OHTN at 3 years 
- Ranibizumab: 9.5% 
- Sham: 3.4% 
 
Freund 
2015 
2419 patients with AMD A, 
A0.5
, R 
-- 96 
weeks 
Various criteria - IOP >21 mmHg at 2 consecutive visits: Rq4: 8.4%, A2q4: 3.2%, A2q8: 4.2%, 
A0.5q4: 2.7% 
- IOP >5 mmHg from baseline at 2 consecutive visits: Rq4: 19.7%, A2q4: 
14.1%, A2q8: 12.6%, A0.5q4: 11.1% 
- Ranibizumab was associated with greater OHTN rates.  
Foss 
2016 
AMD patients in IVAN 
trial, 610 patients 
R, B -- 23.6 
months 
Various criteria - For every month, there was a statistically significant increase in 
preinjection IOP of 0.02mmHg/month 
- Anti-VEGF agent used and pre-existing glaucoma diagnosis was not a risk 
factor for OHTN throughout the study 
- Pseudophakia was associated with a lower IOP 
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Table 4. Studies not finding sustained ocular hypertension following repeated intravitreal injections. 
 
 
 
 
 
 
 
 
 
 
 
Study key: P: pegaptanib, B: Bevacizumab, R: Ranibizumab, IVI: Intravitreal injection, IOP: Intraocular pressure, mmHg: millimeters of mercury, 
OHTN: ocular hypertension, AMD: Age-related macular degeneration 
Study Cohort Medication Follow-up Key IOP inclusion criteria Key findings 
Wehrli 
2012 
302 eyes 
with AMD 
and 226 
control 
fellow eyes 
B, R 2 years IOP ≥22 mmHg on 2 
consecutive visits  with 
an increase from 
baseline of >6 mmHg 
or IOP > 26 mmHg on a 
single visit 
- 0.5% incidence per eye-year of sustained OHTN in 
injected eyes compared to 1.0% of control eyes 
- For patients with glaucoma, 3.1% of patients treated 
with anti-VEGF developed sustained OHTN, 
compared to 5.7% of control eyes 
Boyer 
2014 
221 eyes 
with AMD, 
114 treated 
with P 
P 24 
months 
≥2 measurements of 
≥22 mmHg 
 
- 5.3% of patients receiving pegaptanib versus 9.3% in 
the sham group 
 
Kim 2014 
AJO 
629 eyes with 
AMD and 95 
eyes with RVO 
B, R 35.5 
months 
IOP increase of >5mmHg 
over baseline on 2 
consecutive visits 
- 3.1% of control fellow eyes developed sustained OHTN 
- 3.0% of patients with AMD developed sustained OHTN 
- 7.4% of patients with RVO developed sustained OHTN 
Kim 2014 
J Glauc 
83 patients 
with AMD 
B 24 
months 
Average IOP  - No difference in IOP between groups 
- No comment on the percentage of patients with an 
increase in IOP, as only averages were presented 
- Average of only 3.71 injections 
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Figure 1.  
Weighted IOP average following intravitreal injection. This graph presents the acute change in IOP 
following intravitreal injection. The data for this graph was extracted from material presented in 
Supplemental Material Table 1. This data was then used to create weighted IOP averages based on the 
number of patients included in each study for each of the plotted time points. Error bars were created 
from the weighted standard deviation of the means.  
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Figure 2.  
Prophylactic effect of topical drops given prior to intravitreal injection. The data for this graph was 
extracted from published material presented in Supplemental Material Table 2. This data was used to 
create weighted IOP averages based on the number of patients included at each time point. Error bars 
were not included in this graph due to the paucity of data available and to not give an erroneous 
impression of statistical significance. 
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